Biovica International - Positive Results With DiviTum® From New Pfizer Study Presented at the AACR Congress
UPPSALA, Sweden, April 17, 2018 /PRNewswire/ --
New results from a Pfizer study on Ibrance® (palbociclib, Pfizer) of women with metastatic breast cancer demonstrate that DiviTum can provide fast evaluation of biologic effect demonstrating CDK 4/6 inhibition.
The study, presented at the ongoing AACR congress in Chicago, concluded that using DiviTum to measure cell proliferation in blood samples could potentially be used to assess cell cycle modulation by Ibrance®.
"We are pleased that DiviTum is included by Pfizer in their clinical development of Ibrance®. These positive results are in line with previously presented DiviTum data evaluating biologic effect of demonstrating CDK 4/6 inhibition in connection with treatment of breast cancer. The results take us yet another step closer to our vision of enabling the best possible treatment for cancer patients from day one" says Anders Rylander, CEO Biovica.
Gestalt Diagnostics has added healthcare industry expert, Dr. J. Mark Tuthill, to serve on Gestalt's Advisory Board. He will be joining Gestalt's distinguished Advisory Board of pathologists contributing to oversight and active input of development...
Leading research and experience management firm Sogolytics has released an original study examining the telehealth landscape, highlighting its achievements and challenges in providing positive experiences for patients.
"It's critical for providers...
West Physics Consulting, LLC ("West Physics"), the leading national provider of integrated medical and health physics services, announced today that it has completed the purchase of the medical physics service division of Tricord, Inc. ("Tricord"), a...
Amae Health, a trailblazer in delivering patient-centered care for people with severe mental illness, announced today the successful closing of its oversubscribed $15 million Series A funding round. The round was led by Quiet Capital and included...
Roivios, a pioneering clinical-stage medical device company dedicated to transforming kidney health, is thrilled to announce it has been awarded the prestigious Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its...
Burrell College of Osteopathic Medicine (BCOM) attained the highest level of accreditation from the American Osteopathic Association (AOA) Commission on Osteopathic College Accreditation (COCA). Burrell has been awarded the prestigious accreditation...
